Lambert-Eaton myasthenic syndrome (LEMS)

Brain and Nerve

Volumn 62, Issue 4, 2010, Pages 419-426

  Suzuki, Shigeaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibodies; P Q type voltage gated calcium channels; Paraneoplastic; Small cell lung cancer; Synaptotagmin

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINE; AUTOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; PREDNISOLONE; SYNAPTOTAGMIN ANTIBODY; TRANSCRIPTION FACTOR SOX1 ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL ANTIBODY;

ACETYLCHOLINE RELEASE; AREFLEXIA; AUTOIMMUNE DISEASE; AUTONOMIC DYSFUNCTION; CANCER SURGERY; CEREBELLAR ATAXIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MEGADOSE; EATON LAMBERT SYNDROME; ELECTROPHYSIOLOGY; FAMILY HISTORY; HUMAN; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; NERVE STIMULATION; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PROGNOSIS; PTOSIS; REVIEW;

4-AMINOPYRIDINE; AUTOANTIBODIES; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; LAMBERT-EATON MYASTHENIC SYNDROME; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PLASMA EXCHANGE; SOXB1 TRANSCRIPTION FACTORS; SYNAPTOTAGMINS;

EID: 77951616801     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Clin Neurosci 24: 79-82, 2006
2. Mol Med 40: 832-839, 2003
3. Wirtz PW, van Dijk JG, van Doorn PA, van Engelen BG, van der Kooi AJ, et al: The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 63: 397-398, 2004
4. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 80: 7636-7640, 1983
5. Nagel A, Engel AG, Lang B, Newsom-Davis J, Fukuoka T: Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol 24: 552-558, 1988
6. Hille B, William AC: Electrical excitability and ion channels. In Basic Neurochemistry-Molecular, Cellular, and Medical Aspects. Siegel GJ (ed), Lippincott-Raven Publisher, Philadelphia, 1999, pp 119-137
7. Takamori M, Iwasa K, Komai K: Antibodies to synthetic peptides of the alphalA subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48: 1261-1265, 1997
8. Takamori M, Iwasa K, Komai K: Antigenic sites of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 625-635, 1998
9. Iwasa K, Takamori M, Komai K, Mori Y: Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 54: 757-759, 2000 (Pubitemid 30082956)
10. Komai K, Iwasa K, Takamori M: Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J Neurol Sci 166: 126-130, 1999
11. Pellkofer HL, Armbruster L, Krumbholz M, Titulaer MJ, Verschuuren JJ, et al: Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 204: 136-139, 2008
12. Parsons KT, Kwok WW: Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J Neuroimmunol 126: 190-195, 2002
13. Motomura M, Lang B, Johnston I, Palace J, Vincent A, et al: Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147: 35-42, 1997
14. Iwasa K, Pinto A, Vincent A, Lang B: LEMS IgG binds to extracellular determinants on N-type voltage-gated calcium channels, but does not reduce VGCC expression. Ann N Y Acad Sci 998: 196-199, 2003
15. Martin-Moutot N, De Haro L, Seagar M: Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome. J Neuroimmunol 197: 47-53, 2008
16. Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A: Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann Neurol 35: 74-80, 1994
17. Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, et al: Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 133: 95-101, 1995
18. Takamori M, Komai K, Iwasa K: Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am J Med Sci 319: 204-208, 2000 (Pubitemid 30396579)
19. Takamori M, Motomura M, Fukudome T, Yoshikawa H: Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur J Neurol 14: 1230-1235, 2007
20. Takamori M: Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. Biochem Biophys Res Commun 322: 1347-1351, 2004
21. Takamori M: Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol 201-202: 145-152, 2008
22. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, et al: SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70: 924-928, 2008
23. Titulaer MJ, Klooster R, Potman M, Sabate L, Graus F, et al: SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 27: 4260-4267, 2009
24. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, et al: Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26: 4276-4281, 2008
25. Maddison P, Lang B, Mills K, Newsom-Davis J: Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 70: 212-217, 2001
26. Maddison P, Newsom-Davis J, Mills KR, Souhami RL: Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353: 117-118, 1999
27. Maddison P, Lang B: Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 201-202: 159-162, 2008
28. Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, et al: HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 159: 230-237, 2005 (Pubitemid 40126197)
29. Parsons KT, Kwok WW, Gaur LK, Nepom GT: Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer. Hum Immunol 61: 828-833, 2000
30. Wirtz PW, Bradshaw J, Wintzen AR, Verschuuren JJ: Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. J Neurol 251: 1255-1259, 2004
31. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, et al: Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120: 1279-1300, 1997
32. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, et al: P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59: 764-766, 2002
33. Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, et al: Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53: 21-28, 2003
34. Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, et al: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59: 1773-1775, 2002
35. O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111: 577-596, 1988
36. Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, et al: The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 201-202: 153-158, 2008
37. Ueda T, Kanda F, Kobessho H, Hamaguchi H, Motomura M: "Dropped head syndrome" caused by Lambert-Eaton myasthenic syndrome. Muscle Nerve 40: 134-136, 2009
38. Waterman SA: Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin Auton Res 11: 145-154, 2001
39. O'Suilleabhain P, Low PA, Lennon VA: Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 50: 88-93, 1998
40. Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA: Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50: 1806-1813, 1998
41. Wirtz PW, Sotodeh M, Nijnuis M, van Doorn PA, Van Engelen BG, et al: Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 73: 766-768, 2002
42. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine: Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 24: 1239-1247, 2001
43. Oh SJ, Hatanaka Y, Claussen GC, Sher E: Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 35: 178-183, 2007
44. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J: An improved diagnostic assay for Lambert-Eaton myasüienic syndrome. J Neurol Neurosurg Psychiatry 58: 85-87, 1995
45. Nakao YK, Motomura M, Suenaga A, Nakamura T, Yoshimura T, et al: Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J Neurol 246: 38-44, 1999
46. Martin-Moutot N, Haro L, Santos RG, Mori Y, Seagar M: Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome. Neurobiol Dis 22: 57-63, 2006
47. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40: 1552-1556, 1990
48. Sanders DB, Massey JM, Sanders LL, Edwards LJ: A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54: 603-607, 2000
49. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB: 3, 4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40: 795-800, 2009
50. Oh SJ, Kim DS, Head TC, Claussen GC: Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthienic syndrome. Muscle Nerve 20: 1146-1152, 1997
51. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, et al: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47: 678-683, 1996
52. Motomura M, Hamasaki S, Nakane S, Fukuda T, Nakao YK: Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 4: 287-290, 2000
53. Pellkofer HL, Voltz R, Kuempfel T: Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 40: 305-308, 2009